Intranasal delivery of erythropoietin plus insulin-like growth factor–I for acute neuroprotection in stroke
- 1 July 2009
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 111 (1) , 164-170
- https://doi.org/10.3171/2009.2.jns081199
Abstract
Object: Individually, the cytokines erythropoietin (EPO) and insulin-like growth factor–I (IGF-I) have both been shown to reduce neuronal damage significantly in rodent models of cerebral ischemia. The authors have previously shown that EPO and IGF-I, when administered together, provide acute and prolonged neuroprotection in cerebrocortical cultures against N-methyl-d-aspartate–induced apoptosis. The aim of this study was to determine whether intranasally applied EPO plus IGF-I can provide acute neuroprotection in an animal stroke model and to show that intranasal administration is more efficient at delivering EPO plus IGF-I to the brain when compared with intravenous, subcutaneous, or intraperitoneal administration. Methods: The EPO and IGF-I were administered intranasally to mice that underwent transient middle cerebral artery occlusion (MCAO). Stroke volumes were measured after 1 hour of MCAO and 24 hours of reperfusion. To evaluate the long-term effects of this treatment, behavioral outcomes were assessed at 3, 30, 60, and 90 days following MCAO. Radiography and liquid scintillation were used to visualize and quantify the uptake of radiolabeled 125I-EPO and 125I–IGF-I into the mouse brain after intranasal, intravenous, subcutaneous, or intraperitoneal administration. Results: Intranasal administration of EPO plus IGF-I reduced stroke volumes within 24 hours and improved neurological function in mice up to 90 days after MCAO. The 125I-EPO and 125I–IGF-I were found in the brain within 20 minutes after intranasal administration and accumulated within the injured areas of the brain. In addition, intranasal administration delivered significantly higher levels of the applied 125I-EPO and 125I–IGF-I to the brain compared with intravenous, subcutaneous, or intraperitoneal administration. Conclusions: The data demonstrate that intranasal EPO plus IGF-I penetrates into the brain more efficiently than other drug delivery methods and could potentially provide a fast and efficient treatment to prevent chronic effects of stroke.Keywords
This publication has 26 references indexed in Scilit:
- Intranasal Insulin to Improve Memory Function in HumansNeuroendocrinology, 2007
- Guidelines for the Early Management of Patients With Ischemic StrokeStroke, 2005
- Acute neuroprotective synergy of erythropoietin and insulin-like growth factor IProceedings of the National Academy of Sciences, 2004
- Is nose-to-brain transport of drugs in man a reality?Journal of Pharmacy and Pharmacology, 2004
- Cerebral neurogenesis is induced by intranasal administration of growth factorsAnnals of Neurology, 2003
- Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor miceProceedings of the National Academy of Sciences, 2002
- Cognitive and behavioral assessment in experimental stroke research: will it prove useful?Neuroscience & Biobehavioral Reviews, 2001
- Neurons and astrocytes express EPO mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brainGlia, 2000
- A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in MiceJournal of Cerebral Blood Flow & Metabolism, 1999
- Localization of specific erythropoietin binding sites in defined areas of the mouse brain.Proceedings of the National Academy of Sciences, 1995